Abiopharma

🔍 Bailey Calli Sullivan (Executive)

Company: Nakamoto Inc. (NAKA)

Report Date: 2026-08-25

Detailed Transactions and Holdings:

• Sold 3,844 shares of Common Stock (Direct)
  Date: 2026-08-25 | Code: J | equity_swap_involved: 0 | shares_owned_after: 2,468,300.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: On August 25, 2026, 3,844 shares of Common Stock of Nakamoto Inc. (the "Issuer"), previously held by the Reporting Person, were returned to Issuer to satisfy obligations pursuant to the terms of the Agreement and Plan of Merger, dated February 17, 2026, by and among the Issuer, BTC Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, BTC Inc., a Delaware corporation, and the stockholder representative party thereto.
• F2: The total shares of Issuer Common Stock beneficially owned by the Reporting Person as reported herein reflect the application of a 40:1 reverse stock split disclosed in Issuer's Form 8-K filed on May 21, 2026. In addition, the current filing corrects for the overreporting of the Reporting Person's beneficial ownership in the Reporting Person's Form 3 filing, which included transaction shares that were not beneficially owned by the Reporting Person at that time.